Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Metastatic Ovarian Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Metastatic Ovarian Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - SGN-1 in Metastatic Ovarian Cancer

Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Non-Small Cell Lung Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Non-Small Cell Lung Cancer....

Likelihood of Approval and Phase Transition Success Rate Model - SGN-1 in Non-Small Cell Lung Cancer

Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Sarcomas: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Sarcomas. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - SGN-1 in Sarcomas

Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Metastatic Melanoma: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Metastatic Melanoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - SGN-1 in Metastatic Melanoma

Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC)....

Likelihood of Approval and Phase Transition Success Rate Model - SGN-1 in Metastatic Hepatocellular Carcinoma (HCC)

Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Hepatocellular Carcinoma: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Hepatocellular Carcinoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - SGN-1 in Hepatocellular Carcinoma

Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Metastatic Breast Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Metastatic Breast Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - SGN-1 in Metastatic Breast Cancer

Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Breast Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Breast Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - SGN-1 in Breast Cancer

Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Pancreatic Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase I for Pancreatic Cancer. According to...

Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Liver Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase I for Liver Cancer. According to...